TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum tolerated dose or clinically recommended dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional test 1 to assess musculoskeletal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of Food Waste
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in female sexual function index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HCC incidence rate
Endpoint domain: Mortality/survival
Primary endpoint: Fitting of scallopped stent-graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arrhythmia Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Maximum force produced at zero speed in a fatigue-free condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed in a fatigue-free condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum force produced at zero speed at the end of the 3 min.
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed up produced at the end of the 3 min.
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG QT Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Multiple Sclerosis Work Difficulties Questionnaire -23
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Wrong-patient order sessions with RAR events
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge Level of Cardiopulmonary Resuscitation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lumbar spine bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibial failure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline ICIQ-UI SF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary efficacy on maternal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary efficacy on maternal iron and hematological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preliminary efficacy on neonatal iron and hematological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ventilation Defect Percentage change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pancreas volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of venetoclax in combination with CLAG-M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline socio-cultural perceptions of HIV prevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV test intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV test behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary functionality changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiopulmonary response to physical exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment response rate of Insomnia Severity Index (ISI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage of Participants With Solicited Local and Systemic Adverse Reactions Through 14 Days After Initial Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unsolicited Adverse Events (AEs) Through 28 Days After Initial Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) During Study
Endpoint domain: Adverse events/effects
Primary endpoint: Lung cancer organoid response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reference ranges of placental angiogenesis markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Diameter of the inflammatory reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity difference between trans-hepatic and subcostal window
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity difference between trans-hepatic and subcostal window
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with sustained unresponsiveness to allergenic food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of tolerant participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydrostatic error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scapular muscles activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: development or progression of diabetic nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: development or progression of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of pancreatic insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: International Hip Outcome Tool-33 (iHOT-33)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Black triangle height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in change in parent activation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in change in youth social functioning- life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Difference in change in parent depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Western Ontario and McMaster (WOMAC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Connectedness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Concentration of Serum prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seroconversion for anti-poliovirus neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BOLD activation of the ventral striatum and ventral medial prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glucose Tolerance as Measured by the Oral Glucose Tolerance Test (OGTT) 120 Minutes After Glucose Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive Function as Measured by Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fatigue as Measured by the Multidimensional Fatigue Symptom Inventory
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of mild to moderate gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Intermediate Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of unanticipated adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Medication possession ratio (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Chemotherapy Adherence Scale (OCAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication pill counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of enrolled patients who activated/used the app during the PACU stay
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Time to Complete Mastoid Cavity Epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of leronlimab in combination therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time of occurrence of Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: terminal phase half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate to assess child's dental anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venham picture test used to assess dental anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary Alpha amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wijma Delivery Expectancy/Experience Scale (W-DEQ) Version A
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Limb circumference change from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema change from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb muscle strength change from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients with a CPC score of 1-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in physiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cannabinoid levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endocannabinoid levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of delirium occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Postoperative PVi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative intravenous fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Necrotizing enterocolitis (NEC)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Completing the 3RP-VHL Program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: modified Rankin scale (mRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal imaging-amyloid fluorescent intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal imaging-amyloid fluorescent deposit number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal imaging-amyloid fluorescent location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live donor kidney transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in angina symptom ordinal scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T2 relaxation times in the medial femoral condyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average cartilage strain in the medial femoral condyle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fidelity - sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glycated hemoglobin (HbA1c%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional Disability assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Agitation measured by Cohen-Mansfield Agitation Inventory (CMAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the risk of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of RP2D and Alt-RP2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute Graft vs Host disease (GVHD) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic Graft vs Host disease (GVHD) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: consistency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in positive and negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost
Endpoint domain: Resource use
Primary endpoint: Incidence of grade 3-4 acute and/or chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Level of health literacy regarding neonatal jaundice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The Zarit Care Burden Scale (ZBVYS)
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in patients' engagement in advance care planning (Decision Maker subscale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patients' engagement in advance care planning (Quality of Life subscale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in advance care planning engagement: completion of advance directives
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of pathological regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ivermectin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hands-off time during prehospital cardiopulmonary resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta PPV (T2-T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta SVV (T2-T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tibial plafond inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Talar inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibiotalar tilt angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic efficacy of 68Ga-N188 PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reported health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in number of days mental/physical health were not good
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in reported self-efficacy for managing chronic conditions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the semaglutide plasma concentration-time curve after a single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the NNC0480-0389 plasma concentration-time curve after a single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with new SCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mayo modified wrist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Effective Dose (ED50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Examination - Self-Report Questionnaire (EDE-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Impairment Assessment (CIA)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fear of Food Measure (FOFM)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Receipt of the allocated study drug within 1 hour before start of surgery for the tranexamic acid factorial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Receipt of the allocated study drug within 1 hour before start of surgery for the desmopressin factorial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completion of 30-day follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of inpatient endoscopy delays (IED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum voluntary isometric contraction - Knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum voluntary isometric contraction - Knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of torque development (RTD) for knee extension and flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUCinf of GS-4571
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of GS-4571
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to response to chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial respiratory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial dimension and morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Device Malfunction adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Compliance with Postoperative Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rectal Doxycycline Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Doxycycline Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility (patient level)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability (patient level)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility (provider level)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability (provider level)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status